

**-15%** MNTR Gain since Cancer Immunotherapy Announcement at \$1.01/sh on 7/10/09.

Now at: **\$0.86**

Annualized MNTR Gain:

**-22%**

**67%** Index Gain / 35 wks

## Cancer Immunotherapy Index\*

Annualized Index Gain:

**99%**

**50%**

Versus Gain / 35 wks for (NASDAQ:Biotech + S&P Biotech + NYSE Biotech Indices) / 3

Annualized Average of 3 Indices Gain:

**74%**

Company in CI Index	Symbol	12-Mar Price	10-Jul Start Price	35 week Gain	Market Cap	Cash Eq per Sh	Potential USA Market	MKT / Mkt Cap
<b>Quantum Immunologics, Inc.</b> <i>(MNTR has significant holdings in Quantum Immunologics which is private)</i> (Breast Cancer & OFA / iLRP Universally Expressed on All Cancers Tested)	( Private )	<b>\$16.00</b> **	<b>\$12.00</b>	<b>33%</b>	\$17 M	<b>\$0.96</b>	<b>\$12.0 B</b>	<b>719 x</b>
<b>Dendreon Corporation</b> (Prostate, Breast, Colon, Ovarian, Lung & Kidney Cancers & Monoclonal AB)	( DNDN )	<b>\$36.75</b>	<b>\$23.06</b>	<b>59%</b>	\$4,254 M	<b>\$2.30</b>	<b>\$14.1 B</b>	<b>3 x</b>
<b>Oncothyreon</b> (Lung Cancer)	( ONTY )	<b>\$4.89</b>	<b>\$3.12</b>	<b>57%</b>	\$125 M	<b>\$0.89</b>	<b>\$2.3 B</b>	<b>18 x</b>
<b>Antigenics</b> (Renal, Melanoma & Brain Cancers - Limited results)	( AGEN )	<b>\$0.77</b>	<b>\$1.53</b>	<b>-50%</b>	\$69 M	<b>\$0.18</b>	<b>\$0.1 B</b>	<b>1 x</b>
<b>Biovest International</b> (Non-Hodgkins Lymphoma)	( BVTI.OB )	<b>\$1.22</b>	<b>\$0.35</b>	<b>249%</b>	\$118 M	<b>\$0.01</b>	<b>\$0.5 B</b>	<b>4 x</b>
<b>Celldex Therapeutics, Inc.</b> (Brain Cancer & Monoclonal Antibodies)	( CLDX )	<b>\$5.24</b>	<b>\$7.10</b>	<b>-26%</b>	\$170 M	<b>\$2.20</b>	<b>\$6.2 B</b>	<b>36 x</b>
<b>ImmunoCellular Therapeutics, Ltd.</b> (Peptide Based & Stem Cell)	( IMUC.OB )	<b>\$1.00</b>	<b>\$0.30</b>	<b>233%</b>	\$15 M	<b>\$0.18</b>	<b>\$4.6 B</b>	<b>311 x</b>
<b>Northwest Biotherapeutics, Inc.</b> (Prostate, Brain, Lung & Ovarian Cancers - Less proprietary, Cash Noted)	( NWBO.OB )	<b>\$0.82</b>	<b>\$0.75</b>	<b>9%</b>	\$48 M	<b>\$0.00</b>	<b>\$0.2 B</b>	<b>3 x</b>
<b>CEL-SCI Corporation</b> (Head and Neck Cancers & Cytokines)	( CVM )	<b>\$0.72</b>	<b>\$0.40</b>	<b>82%</b>	\$108 M	<b>\$0.04</b>	<b>\$3.2 B</b>	<b>30 x</b>
<b>Generex Biotechnology Corporation</b> (Breast & Prostate Cancers)	( GNBT )	<b>\$0.63</b>	<b>\$0.55</b>	<b>13%</b>	\$154 M	<b>\$0.06</b>	<b>\$0.9 B</b>	<b>6 x</b>
<b>Provectus Pharmaceuticals, Inc.</b> (Melanoma)	( PVCT.OB )	<b>\$1.33</b>	<b>\$1.04</b> <small>(Added 2-22-'10)</small>	<b>27%</b>	\$86 M	<b>\$0.06</b>	<b>\$1.0 B</b>	<b>12 x</b>
<b>CANCER IMMUNOTHERAPY INDEX</b> (\$1,000 Total - Invested Equally at Index Start-up on July 10, 2009)		<b>\$1,667</b>	<b>\$1,000</b>	<b>67%</b>	<b>\$5,078 M</b>	<b>13%</b>	<b>\$45.0 B</b> ***	<b>9 x</b>

\* Cancer Immunotherapy Index developed with Mike Havrilla, PhD., Editor of BioMedReports.com, initially as a sub-set to his Cancer Diagnostic & Therapeutic Micro-Cap Index.

\*\* 33.3% gain reflects MNTR private bids at \$16 and matches corresponding 33.66% gain by MNTR during 22 week period in which MNTR substantially held only QI.

\*\*\* Market Data from National Cancer Institute based on Relative Mortality in company treatment areas & 50% penetration by immunotherapy sector into cancer treatments.